Hermann (Teddy) Bär

Everyone is talking about the German biotech financing gap, but are you aware of the many success stories written by the sector?   German biotech companies not only grew significantly across key industry metrics but also capture the global spotlight with their innovative power: ·        Strong growth in number of employees and R&D expenses ·        Revenues and market capitalization pointing upward over the long term ·        Biotech drug developers expanding their therapeutic pipelines ·        Alliances "biobucks" on high level (€11.4 billion) ·        Large-volume M&A deals in the first quarter of 2024 (€5.0 billion)   Furthermore, I am deeply impressed by Germany's biotech innovators who are leading the charge with breakthroughs in: ·        Next-generation radiopharmaceuticals ·        Microbiome-based therapeutics ·        Cutting-edge gene and cell therapies ·        Smart biotech materials ·        Revolutionary novel foods ·        And last but certainly not least, AI-powered solutions throughout various biotech application areas Dive into our German Biotechnology Report 2024 for an in-depth look at these success stories and more – of course we also analyze the German biotech financing gap: https://lnkd.in/egnQsNa4   What are the biotech achievements that inspire you the most? Share them in the comments!        #EYBiotech #BioDeutschland #Biotechnologie

50

1 Kommentar

Salary Guide 2024 - Venture Capital DACH The last two years were crisis years for many start-ups. The volume of financing fell by almost two thirds. The reasons for this are persistently high interest rates and high inflation, coupled with a recession and a difficult geopolitical situation. Added to this is the further withdrawal of foreign investors from financing German start-ups, particularly from the USA. Nevertheless, experts are optimistic about the current year, not least because of the enormous potential in the artificial intelligence and clean tech sectors. This optimistic outlook for 2024 is also reflected in the salaries of VC company employees. These have remained relatively stable and, in some cases, have seen a positive upward trend. #investmentbanking

6

1 Kommentar

𝗖𝗹𝗼𝗻𝗲 𝗼𝗿 𝗖𝘂𝘀𝘁𝗼𝗺𝗶𝘇𝗲? 𝗡𝗮𝘃𝗶𝗴𝗮𝘁𝗶𝗻𝗴 𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗘𝘅𝗽𝗮𝗻𝘀𝗶𝗼𝗻 Today, I ran into a former international CEO on the train. We had only five minutes as I was on my way to an appointment, but we sparked a debate that I just had to bring here: When companies expand into new countries, should their main focus be on transplanting their existing culture or adapting to the local culture? 𝗖𝗹𝗼𝗻𝗶𝗻𝗴 𝗖𝘂𝗹𝘁𝘂𝗿𝗲: Some argue for replicating the original culture, ensuring that the company's core values and brand identity remain consistent worldwide. This approach guarantees that the essence of what made the company successful at home is preserved abroad. But is this sustainable in the culturally diverse global market? 𝗔𝗱𝗮𝗽𝘁𝗶𝗻𝗴 𝗟𝗼𝗰𝗮𝗹𝗹𝘆: Others advocate for adapting to the local environment, tailoring operations and practices to fit cultural norms and customer preferences in each new market. This flexibility can foster local engagement and trust, potentially driving greater success. Yet, does this risk diluting the original corporate identity? I have experience myself from expanding internationally and I know it is never black/ white, there is always some elements of both, but I see there are differences in philosophy and it influences how the expansion takes place. We didn't get to finish our debate, so I’m turning to my network: What are your thoughts on the best approach for global expansion? Which aspect should take front stage?

19

16 Kommentare

Thanks Trending Topics! Georg Haas and I had a super interesting chat about the relevance and importance of innovation in the healthcare ecosystem. Join us as we discuss our recent investment in Rivia and how Erik Scalfaro and his team are disrupting clinical trials from scratch! 🚀 🏥

22

6 Kommentare

The Handelsblatt Research Institute has once again identified Germany's top personnel consultants, and MU is keeping its place as one of the top 40 recruitment consultancies. In collaboration with The IQ Company, The Handelsblatt Research Institute has identified the 40 leading HR consulting companies of 2024. They used the reviews of over 20,500 employees from 2,800 companies as well as the opinions of around 48,000 managers and human resources managers. Whilst doing the review, Handelsblatt also took the opportunity to do a study to look at the biggest challenges that recruiters currently face. The need for AI experts is reflected in the study, where AI and robotics have significantly risen in importance among industry topics. The study also identifies digitalisation and sustainability as top priorities for HR consultants in Germany, reflecting the country's need for managers capable of driving structural change. You can find the online article from Handelsblatt entitled “These are the best HR consultants in Germany” here: https://lnkd.in/egS4G9eX Thank you, Handelsblatt for again recognising MU as a top recruitment firm in Germany! Read more in our press room here: https://lnkd.in/eCGVcqQ9

5

Half-year update on German biotech venture investments H1 2024 saw German biotech VC investments hit €494M, 93% of 2023's total. Big bets of €316M show trust in top-class companies. Other VC-backed firms got €178M, with sustainable food innovators gaining traction. For more info on the state of the industry as well as current trends and challenges, download the German Biotechnology Report 2024. https://go.ey.com/4ctMX31 #BioDeutschland #Biotechnology

20

2 Kommentare

The Handelsblatt Research Institute has once again identified Germany's top personnel consultants, and MU is keeping its place as one of the top 40 recruitment consultancies. In collaboration with The IQ Company, The Handelsblatt Research Institute has identified the 40 leading HR consulting companies of 2024. They used the reviews of over 20,500 employees from 2,800 companies as well as the opinions of around 48,000 managers and human resources managers. Whilst doing the review, Handelsblatt also took the opportunity to do a study to look at the biggest challenges that recruiters currently face. The need for AI experts is reflected in the study, where AI and robotics have significantly risen in importance among industry topics. The study also identifies digitalisation and sustainability as top priorities for HR consultants in Germany, reflecting the country's need for managers capable of driving structural change. You can find the online article from Handelsblatt entitled “These are the best HR consultants in Germany” here: https://lnkd.in/di4SGGfT Thank you, Handelsblatt for again recognising MU as a top recruitment firm in Germany! Read more in our press room here: https://lnkd.in/dq4NTmd5

1

Investor media in Germany – where Vidac Pharma is listed - have started paying attention to the company. In an article called “The oncology therapy race worth billions”, the Finanznachrichten website mentions Vidac as one of three companies that could benefit from a new “Golden Era” for cancer therapy. And in another story, the website identifies Vidac as a takeover candidate after Novartis’s acquisition of Morphosys in February. Look at these two stories here https://shorturl.at/dqtwJ and (in German) here: https://shorturl.at/tJQY7 Vidac Pharma is developing a new class of cancer drugs that reverses the abnormal metabolism common to all cancer cells. While the phenomenon was discovered a hundred years ago, surprisingly, no drugs have been developed to target it. Early results with Vidac’s two drug candidates give hope they can be applied across a wide range of tumors. #biotech #oncology #drugdevelopment #bioscience #cancer

11

Skipping the needle: ETH Zürich spin-off OBaris works on a revolutionary way of delivering injectable drugs, without pain. Innovators Nevena Paunović and David Klein Cerrejon explain the technology and introduce their startup: About: millions of patients face the discomfort of daily injections due to their dependence on medications that cannot be taken orally. OBaris has developed a needle-free alternative, named “OctoPatch”, in the form of a painless suction patch applied to the inner cheek, which allows the drugs to enter the bloodstream efficiently. OBaris aims to access the rapidly growing market of therapeutic peptides, with an overall size of ca. CHF 40 billion in 2023. Its goal is to provide a painless alternative to patients across multiple therapeutic indications, with a focus on metabolic diseases, such as diabetes, obesity, and osteoporosis. OBaris also aims to partner with leading pharmaceutical companies to make its solution available for an even broader population of patients. OBaris will invest the CHF 150’000 from Venture Kick to validate its regulatory strategy and initiate the first meeting with the FDA, organize the scale-up manufacturing, and further prepare for the fundraising by meeting with international investors. Read more: https://lnkd.in/e74rjbEC #VentureKick #SwissStartups

60

1 Kommentar

🚀 Transforming Healthcare Through Digitalisation: Key Insights from Healthcare Professionals in Switzerland digitalswitzerland digital health study on the perspectives of healthcare professionals is now live! 👉 https://lnkd.in/dzEH4U_C Swiss citizens are willing to embark on a digital healthcare journey, whereas healthcare professionals (HCPs) face concerns with the fear of  increased workloads and non-intuitive systems. Our study reveals how to empower HCPs to adopt digital health tools effectively based on in-depth interviews.  By involving HCPs and addressing their needs, we can enhance healthcare delivery and patient outcomes. Let's support our healthcare professionals on this transformative journey! 🌐💡 Bryan Quak Jade Sternberg Sebastiano Caprara Nathalie Daina-Laville Geigy Nicolas Conrad Eric Müller #digitalswitzerland #DigitalHealth #HealthcareInnovation #HCPs #DigitalTransformation #HealthcareTech #PatientCare #FutureOfHealth What digital health tools do you use? 👇

25

1 Kommentar

We are pleased to present the EY German Biotech Report 2024, which has been produced in close cooperation with BIO Deutschland e. V..   This year we are devoting special attention to the topic of AI in biotechnology. From simulating clinical trials to developing personalized medicines, AI holds the promise of ushering in the next wave of bioscientific innovation. For a deeper dive, download the full EY German Biotech Report 2024: https://lnkd.in/egnQsNa4   Let's discuss the future of biotech and AI – I welcome your thoughts and questions in the comments below.   #EYBiotech #BioDeutschland #Biotechnologie

224

6 Kommentare

Each year Board Directors from across Switzerland gather to discuss the most important topics. This year Board Effectiveness was in the spotlight and MU Board and CEO Practice team ran workshops on how to evaluate and improve Board performance. What to do – and not do – to secure an Effective and Inclusive Board for your organisation: What is best practice in testing and developing Board effectiveness? What is Best practice in test and improving Board inclusion? What are the ‘no ‘go’s’ when it comes to testing and developing Boad effectiveness? To answer these key questions, participating Board Chairs and Non-Executive Directors added their insights to data collected from the MU BoardScan™. The result of the day was a comprehensive summary of Board Effectiveness best practice. Christian Schaffenberger, Mieke Weijenberg and Richard Moore form MU’s Board and CEO Practice tell us more about what was discussed – concluding on the top 3 answer to the most important questions Board Chairs and Non-Executive Directors raised. Read the article here: https://lnkd.in/e_FqTNsr

2

Each year Board Directors from across Switzerland gather to discuss the most important topics. This year Board Effectiveness was in the spotlight and MU Board and CEO Practice team ran workshops on how to evaluate and improve Board performance. What to do – and not do – to secure an Effective and Inclusive Board for your organisation: What is best practice in testing and developing Board effectiveness? What is Best practice in test and improving Board inclusion? What are the ‘no ‘go’s’ when it comes to testing and developing Boad effectiveness? To answer these key questions, participating Board Chairs and Non-Executive Directors added their insights to data collected from the MU BoardScan™. The result of the day was a comprehensive summary of Board Effectiveness best practice. Christian Schaffenberger, Mieke Weijenberg and Richard Moore form MU’s Board and CEO Practice tell us more about what was discussed – concluding on the top 3 answer to the most important questions Board Chairs and Non-Executive Directors raised. Read the article here: https://lnkd.in/eCYQDi5m

5

Exciting News from D11Z. Ventures GmbH & Co. KG! 🎉 Our portfolio company, seleon GmbH, has reached a significant milestone with its successful acquisition by aesco SOLUTIONS! This strategic move strengthens aesco solutions' position as a leading growth platform in the life sciences sector, while seleon GmbH continues to innovate and expand within the new group. Highlights:   ▪ Growth Potential: seleon GmbH, a MedTech service provider, is set to develop the Heilbronn site into a central hub for medical technology services.   ▪ Innovative Synergy: Integration with aesco solutions will enhance seleon's service offerings, from development and prototyping to series production.   ▪ Industry Impact: This partnership will accelerate innovation, reduce time-to-market for medical devices, and drive economic growth in the region. We celebrate this achievement and look forward to witnessing the continued success of seleon GmbH as part of the aesco solutions family. 👏 A special thank you to the following individuals for their contributions:   Seleon Management: Frank-Martin Rammelt Marina Ring Peter Hartung Roman Gruler Hisnija Schilling Jens Kunath   Bryan Garnier: Raphaël Bidaut Maximilian Thyssen   HEUKING: Hermann Ali Hinderer Marcel Behrendt   EY: Claudio Chiandussi   Advisor to Minority Shareholders: Tobias Lenz   Buyer Side: Alexander Wagner (Aurelius) Florian Scheck (Aurelius) Peter Molnar (aesco solutions)   For more details, check out the full press release linked in our comments below. 📄 #VC #MedTech #VentureCapital #StartupEcosystem #Innovation #D11ZVentures

68

7 Kommentare

We are all wired differently. We are.   And still, we can connect. If we try.   And if we do, the fun begins.   Connect with me or any other coach in my network.   It is never too late to invest in yourself.     Contact: info@driebergencoaching.ch.     Image: the fantastic Ben Ampil 🔺 ____________________________   😎 Hi, I am Reinoud. 👉 Helping you to grow as a manager or leader. 👍 No nonsense, practical, results-oriented leadership coach.   If you like my posts, ring the 🔔 on my Profile, and share this post with your network.   #leadershipcoaching #creativeleadership #leadershipdevelopment  #resilience #psychologicalsafety #leadershipcircle #selfawareness #personaldevelopment #growth  

2

Each year Board Directors from across Switzerland gather to discuss the most important topics. This year Board Effectiveness was in the spotlight and MU Board and CEO Practice team ran workshops on how to evaluate and improve Board performance. What to do – and not do – to secure an Effective and Inclusive Board for your organisation: What is best practice in testing and developing Board effectiveness? What is Best practice in test and improving Board inclusion? What are the ‘no ‘go’s’ when it comes to testing and developing Boad effectiveness? To answer these key questions, participating Board Chairs and Non-Executive Directors added their insights to data collected from the MU BoardScan™. The result of the day was a comprehensive summary of Board Effectiveness best practice. Christian Schaffenberger, Mieke Weijenberg and Richard Moore form MU’s Board and CEO Practice tell us more about what was discussed – concluding on the top 3 answer to the most important questions Board Chairs and Non-Executive Directors raised. Read the article here: https://lnkd.in/erejiKaM

1

An interesting interview with Florian Feddeck from Private Assets SE & Co. KGaA on the topic of digitalization and leadership selection. Thanks for sharing! #mercuriurval #privateequity #executivesearch #specialsituation

29